[Legal Guide] Defending Laboratories Against Unlawful Genetic Testing Referral Claims

#Legal #Guide #Defending #Laboratories #Against #Unlawful #Genetic #Testing #Referral #Claims

Legal DNA Test vs Non Legal DNA Test by Paternity University

Title: Legal DNA Test vs Non Legal DNA Test
Channel: Paternity University
[Expert View] Top Healthcare Lawyers Detail The Chief Compliance Officer’S Liability Risks

[Legal Guide] Defending Laboratories Against Unlawful Genetic Testing Referral Claims

The genetic testing market has experienced explosive growth over the past decade. With this expansion has come unprecedented regulatory scrutiny from the Department of Justice (DOJ), the Office of Inspector General (OIG), and the Department of Health and Human Services (HHS).

For clinical laboratories, navigating the complex web of federal and state fraud and abuse laws is a constant challenge. A single compliance misstep in how genetic testing referrals are sourced, marketed, or compensated can trigger devastating civil and criminal investigations.

This legal guide outlines the primary statutory frameworks governing genetic testing referrals, identifies common enforcement triggers, and provides actionable defense strategies for laboratories facing unlawful referral claims.

Understanding the Legal Landscape of Genetic Testing Referrals

To defend against allegations of unlawful referrals, a laboratory must first understand the three distinct federal pillars of healthcare fraud enforcement: the Anti-Kickback Statute (AKS), the Stark Law, and the Eliminating Kickbacks in Recovery Act (EKRA).

The Anti-Kickback Statute (AKS)

The AKS (42 U.S.C. § 1320a-7b(b)) is a criminal statute that prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration (directly or indirectly) to induce or reward referrals of items or services reimbursable by a federal healthcare program (e.g., Medicare or Medicaid).

The "One Purpose" Test: Courts have consistently held that if even one purpose of a payment is to induce referrals, the AKS is violated, regardless of other legitimate business reasons for the arrangement.

The Stark Law (Physician Self-Referral Law)

The Stark Law (42 U.S.C. § 1395nn) is a strict liability civil statute. It prohibits physicians from making referrals for "Designated Health Services" (DHS)—which explicitly includes clinical laboratory services—to an entity with which the physician (or an immediate family member) has a financial relationship, unless a specific exception applies. Because it is a strict liability statute, proof of intent to violate the law is not required.

The Eliminating Kickbacks in Recovery Act (EKRA)

Enacted in 2018 as part of the SUPPORT Act, EKRA (18 U.S.C. § 220) is a criminal statute that closely mirrors the AKS but with two critical differences:

Payor-Agnostic: EKRA applies to services covered by all health care benefit programs, including private commercial insurance, not just federal programs.
Strict Employee Compensation Rules: Unlike the AKS, which contains a broad safe harbor for bona fide employment relationships, EKRA prohibits paying employees or independent contractors compensation that varies based on the number of individuals referred, tests performed, or amount billed.

Common Allegations and Triggers for Government Investigations

Federal investigators routinely target genetic testing laboratories (specifically those performing Cancer Genomics [CGx] and Pharmacogenomics [PGx] testing) based on specific operational patterns.

Telehealth and Lead Generation Schemes

A primary trigger for DOJ investigations involves laboratories partnering with third-party marketing or "lead generation" companies. These marketers often use telemarketing to recruit Medicare beneficiaries for genetic tests, then route the patient data to telehealth physicians who sign off on the laboratory orders.

If the physician orders the test without establishing a valid doctor-patient relationship, conducting a proper clinical evaluation, or verifying medical necessity, the government will view the transaction as an unlawful referral scheme.

Independent Contractor Sales Commissions

Many laboratories historically compensated independent (1099) sales representatives using percentage-based commissions. Under the AKS and EKRA, paying volume-based or value-based compensation to independent contractors for securing genetic testing referrals is highly scrutinized and frequently classified as an illegal kickback.

"Medical Necessity" and Ordering Panel Overutilization

The government frequently alleges that laboratories encourage the use of broad, pre-packaged genetic panels (e.g., testing for dozens of unrelated genetic mutations) for every patient, regardless of their specific clinical presentation or family history. When laboratories perform and bill for these comprehensive panels without individualized medical necessity documentation from the ordering physician, it triggers audits and potential False Claims Act (FCA) liability.

Key Defense Strategies for Laboratories

When a laboratory is served with a Civil Investigative Demand (CID), a subpoena, or a complaint alleging unlawful genetic testing referrals, immediate and strategic legal defense is required.

1. Asserting Safe Harbors and Exceptions

The regulatory framework provides specific safe harbors (under the AKS) and exceptions (under the Stark Law) that shield arrangements from liability if all regulatory conditions are met.

The Bona Fide Employment Safe Harbor (AKS): If marketing or sales personnel are W-2 employees, compensation structures that would otherwise violate the AKS may be protected. However, this defense must be carefully balanced against EKRA’s stricter employee compensation rules.
Personal Services and Management Contracts Safe Harbor: For arrangements with 1099 contractors or marketing agencies, laboratories must demonstrate that compensation was set in advance, consistent with Fair Market Value (FMV), and did not take into account the volume or value of referrals.

2. Demonstrating Independent Medical Necessity

A robust defense hinges on proving that the laboratory did not influence or dictate the physician’s clinical decision-making.

Objective Requisition Forms: Provide evidence that the laboratory's requisition forms allowed physicians to select individual tests rather than forcing them into all-or-nothing panels.
Physician Documentation: Present signed medical records demonstrating that the ordering physician made an individualized, clinically supported determination that the genetic test was necessary for the patient's diagnosis or treatment plan.

3. Auditing and Remediation of Sales Representative Contracts

If a laboratory discovers that its legacy marketing arrangements or sales commissions do not fully comply with evolving EKRA interpretations, proactive remediation is critical.

Restructuring to Flat-Rate Compensation: Transitioning 1099 sales reps from percentage-based commissions to fixed, flat-rate compensation models based on Fair Market Value (FMV) for hours worked or services rendered.
Voluntary Self-Disclosure: In cases where systemic compliance failures are identified internally, utilizing the OIG’s Provider Self-Disclosure Protocol (SDP) can significantly reduce potential damages and avoid exclusion from federal programs.

Comparative Analysis: AKS vs. EKRA in Genetic Testing

Building a Proactive Compliance Program to Mitigate Risk

The best defense against an unlawful referral claim is a proactive, rigorously enforced compliance program. Laboratories should implement the following steps immediately to minimize regulatory exposure:

Actionable Compliance Checklist for Lab Executives

Conduct Regular Fair Market Value (FMV) Reviews: Obtain independent, third-party FMV valuations for all marketing, sales, and consulting agreements. Keep these valuations on file to prove the laboratory did not pay above-market rates to secure referrals.
Implement Strict Telehealth Vendor Vetting: If accepting orders from telehealth networks, verify that the network's physicians have established valid doctor-patient relationships, perform comprehensive clinical reviews, and maintain independent medical records.
Train Sales and Marketing Staff: Conduct annual, documented training sessions for all sales representatives regarding AKS, Stark Law, and EKRA boundaries. Prohibit staff from offering "swag," free services, or administrative assistance to physician offices in exchange for referrals.
Perform Routine Internal Claims Audits: Periodically audit a randomized sample of genetic testing claims to verify that the corresponding medical records contain clear documentation of medical necessity.

Conclusion & Next Steps

Defending a genetic testing laboratory against allegations of unlawful referrals requires a sophisticated understanding of how the AKS, Stark Law, and EKRA intersect. Because these laws carry severe civil and criminal penalties—including exclusion from federal healthcare programs—laboratories must treat any regulatory inquiry or internal compliance red flag with the utmost urgency.

If your laboratory has received a subpoena, a Civil Investigative Demand (CID), or is seeking to audit and restructure its marketing arrangements, consult with specialized healthcare defense counsel immediately to protect your business, your license, and your reputation.

[Warning] Forfeiting Rights Against Other Third Parties In Broad Settlement Agreements

How Should the U.S. Regulate Genetic Testing Professional, Patient and Payor Perspectives by Stanford Law School

Title: How Should the U.S. Regulate Genetic Testing Professional, Patient and Payor Perspectives
Channel: Stanford Law School
[How-To] How To Choose A Medical License Defense Attorney With Board Hearing Experience

Legal DNA Testing which test is best for my client - 170322 by AlphaBiolabs

Title: Legal DNA Testing which test is best for my client - 170322
Channel: AlphaBiolabs

CLB Symposium Legal and Regulatory by Stanford Law School

Title: CLB Symposium Legal and Regulatory
Channel: Stanford Law School